Katsuaki Maehara: Removal of ICIs resistance by CAF-derived TSG-6 inhibition
Katsuaki Maehara, Cancer Biologist, shared a post on X:
“Removal of ICIs resistance by CAF-derived TSG-6 inhibition
It is well known that TAMs and CAFs in the tumor microenvironment are key players in ICIs resistance.
In this paper, we found that TSG-6 secreted by CAF in ICIs-resistant pancreatic cancer acts on CD44 of suppressive macrophages to form an immunosuppressive environment.
The administration of TSG-6 neutralizing antibody + PD-1 antibody + CTLA4 antibody in a xenograft model confirmed the following:
・Decrease in suppressive macrophages and Tregs
・Increase in CD8+ T cells
・Prolongation of survival period.
There is certainly a synergistic effect with ICIs, but with this level of drug efficacy, it is not clear if there will be a clinical introduction.
CAFs also play a role in physically blocking the infiltration of immune cells, so a drug that kills CAFs themselves may be more effective than suppressing the liquid factor of CAFs.”
Source: Katsuaki Maehara/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023